Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oncolytic herpes simplex virus PTEN-L (oHSV-P10)
- Development stage
- Preclinical
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral
01
Overview
oHSV-P10 is an oncolytic herpes simplex virus (oHSV) genetically engineered to express a translational variant of the tumor suppressor PTEN, called PTEN-L, which can be secreted and taken up by neighboring cells[3]. This virus is designed to target glioblastoma (GBM) by reducing the enrichment of glioma stem cells (GSCs), which are thought to contribute to therapy resistance and tumor recurrence[1][3]. Mechanistically, oHSV-P10 decreases GSC populations by inhibiting the IL6/JAK/STAT3 signaling pathway, leading to reduced expression of stemness markers like Sox2 and Nestin, and increased differentiation markers like GFAP[1][3][5]. The virus also impairs DNA damage repair in tumor cells, thereby sensitizing them to radiation therapy[1][3]. Preclinical studies show that oHSV-P10, when combined with radiation, improves survival in animal models of GBM[1][3]. The virus is considered a next-generation oHSV and is under development for clinical translation[3].
- Other names
- PTEN-L-expressing oncolytic herpes simplex virus
02
Targets
DNA-PK (DNA-dependent protein kinase)IL-6 (Interleukin 6)JAK (Janus kinase family)PTEN (Phosphatase and tensin homolog deleted on chromosome ten)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on oncolytic herpes simplex virus PTEN-L (oHSV-P10).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oncolytic herpes simplex virus PTEN-L (oHSV-P10).